drugset / Trial / NCT06790888
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
Not yet recruiting
78 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sinocelltech Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed after first-line steroid therapy. Participants will be randomly assigned to one of two treatment groups and followed for 52 weeks to assess response rates and safety.
Timeline
- Start
- 2025-02
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eltrombopag | Small molecule | 2.5 mg | Oral |
| Subject | ripertamab | Monoclonal antibody | 375 mg/m2 | Intravenous |